Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HRTX Stock Forecast 2025-2026
$1.35
Current Price
$247.54M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to HRTX Price Targets
+344.4%
To High Target of $6.00
+233.3%
To Median Target of $4.50
+122.2%
To Low Target of $3.00
HRTX Price Momentum
+15.4%
1 Week Change
+22.7%
1 Month Change
-22.9%
1 Year Change
-11.8%
Year-to-Date Change
-49.6%
From 52W High of $2.68
+35.0%
From 52W Low of $1.00
📊 TOP ANALYST CALLS
Did HRTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Heron is one of their latest high-conviction picks.
Latest HRTX Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, HRTX has a bullish consensus with a median price target of $4.50 (ranging from $3.00 to $6.00). The overall analyst rating is N/A (N/A/10). Currently trading at $1.35, the median forecast implies a 233.3% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Brandon Folkes at HC Wainwright & Co., projecting a 344.4% upside. Conversely, the most conservative target is provided by Serge Belanger at Needham, suggesting a 122.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HRTX Analyst Ratings
4
Buy
0
Hold
0
Sell
HRTX Price Target Range
Low
$3.00
Average
$4.50
High
$6.00
Current: $1.35
Latest HRTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HRTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 8, 2025 | Needham | Serge Belanger | Buy | Maintains | $3.00 |
| Jun 9, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Initiates | $6.00 |
| Apr 11, 2025 | Needham | Serge Belanger | Buy | Reiterates | $4.00 |
| Feb 28, 2025 | Needham | Serge Belanger | Buy | Reiterates | $4.00 |
| Dec 4, 2024 | Needham | Serge Belanger | Buy | Reiterates | $4.00 |
| Nov 13, 2024 | Needham | Serge Belanger | Buy | Maintains | $4.00 |
| Sep 25, 2024 | Needham | Serge Belanger | Buy | Reiterates | $5.00 |
| Aug 7, 2024 | Needham | Serge Belanger | Buy | Reiterates | $5.00 |
| Jun 13, 2024 | Rodman & Renshaw | Brandon Folkes | Buy | Initiates | $7.00 |
| May 16, 2024 | Needham | Serge Belanger | Buy | Reiterates | $5.00 |
| May 8, 2024 | Needham | Serge Belanger | Buy | Reiterates | $5.00 |
| Apr 23, 2024 | Capital One | Tim Chiang | Overweight | Initiates | $6.00 |
| Apr 11, 2024 | Needham | Serge Belanger | Buy | Reiterates | $5.00 |
| Mar 13, 2024 | Needham | Serge Belanger | Buy | Maintains | $5.00 |
| Nov 15, 2023 | Needham | Serge Belanger | Buy | Maintains | $4.00 |
| Aug 15, 2023 | Needham | Serge Belanger | Buy | Reiterates | $5.00 |
| Jul 25, 2023 | Needham | Buy | Maintains | $N/A | |
| May 12, 2023 | Needham | Serge Belanger | Buy | Maintains | $6.00 |
| Apr 21, 2023 | Needham | Serge Belanger | Buy | Reiterates | $7.00 |
| Mar 24, 2023 | Evercore ISI Group | Shweta Khajuria | Outperform | Maintains | $10.00 |
Heron Therapeutics Inc. (HRTX) Competitors
The following stocks are similar to Heron based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Heron Therapeutics Inc. (HRTX) Financial Data
Heron Therapeutics Inc. has a market capitalization of $247.54M with a P/E ratio of -15.0x. The company generates $155.10M in trailing twelve-month revenue with a -8.8% profit margin.
Revenue growth is +16.5% quarter-over-quarter, while maintaining an operating margin of -10.7% and return on equity of +40.4%.
Valuation Metrics
Market Cap
$247.54M
Enterprise Value
$333.02M
P/E Ratio
-15.0x
PEG Ratio
-0.1x
Price/Sales
1.5x
Growth & Margins
Revenue Growth (YoY)
+16.5%
Gross Margin
+68.8%
Operating Margin
-10.7%
Net Margin
-8.8%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+22.4%
Current Ratio
2.6x
Debt/Equity
943.5x
ROE
+40.4%
ROA
+0.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Heron Therapeutics Inc. (HRTX) Business Model
About Heron Therapeutics Inc.
What They Do
Develops innovative therapeutic treatments for cancer and pain.
Business Model
Heron Therapeutics generates revenue through the development and commercialization of therapeutic treatments aimed at addressing unmet medical needs, primarily in oncology and pain management. The company focuses on creating advanced drug delivery systems that enhance treatment efficacy and safety, which can lead to marketable products that improve patient outcomes.
Additional Information
Heron Therapeutics is engaged in clinical development, emphasizing innovative approaches to drug delivery that can significantly impact healthcare practices and expenditures. Their work aims to provide breakthroughs in treatment options, potentially leading to reduced need for ongoing interventions and better overall patient care.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
122
CEO
Mr. Craig Alexander Collard
Country
United States
IPO Year
1987
Website
www.herontx.comHeron Therapeutics Inc. (HRTX) Latest News & Analysis
Latest News
Quick Summary
Heron Therapeutics' APONVIE® has been included in the Fifth Consensus Guidelines for Managing Postoperative Nausea and Vomiting, published in Anesthesia and Analgesia.
Why It Matters
Heron Therapeutics’ inclusion of APONVIE® in key medical guidelines may boost its credibility, demand, and market share, potentially leading to increased revenue and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Heron Therapeutics, Inc. (HRTX) will hold its Q3 2025 earnings call on November 4, 2025, at 8:30 AM EST, featuring key executives and analysts from various firms.
Why It Matters
The earnings call provides key insights into Heron Therapeutics’ financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
1 month ago
Quick Summary
Heron Therapeutics reported Q3 2025 net revenue of $38.2 million, up 49% for ZYNRELEF and 173% for APONVIE. Year-to-date revenue reached $114.3 million, maintaining guidance of $153-$163 million for 2025.
Why It Matters
Heron Therapeutics reported strong Q3 revenue growth, particularly from ZYNRELEF and APONVIE, indicating effective marketing strategies and potential for exceeding revenue guidance, which may boost investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Heron Therapeutics (HRTX) reported its revenue and EPS for Q3 2025, which should be evaluated against Wall Street estimates and year-ago figures for comprehensive analysis.
Why It Matters
Revenue and EPS compared to estimates and prior year figures indicate Heron Therapeutics' growth trajectory and market positioning, influencing investor sentiment and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Heron Therapeutics (HRTX) reported a quarterly loss of $0.05 per share, exceeding the Zacks Consensus Estimate of a $0.02 loss, compared to a $0.03 loss per share a year prior.
Why It Matters
Heron Therapeutics' larger-than-expected quarterly loss signals potential operational challenges, which could impact investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Heron Therapeutics appointed Thomas Cusack to its Board of Directors, enhancing its corporate governance, following a Cooperation Agreement with Rubric Capital Management.
Why It Matters
The appointment of Thomas Cusack strengthens Heron Therapeutics' governance and finance expertise, potentially enhancing investor confidence and impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About HRTX Stock
What is Heron Therapeutics Inc.'s (HRTX) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Heron Therapeutics Inc. (HRTX) has a median price target of $4.50. The highest price target is $6.00 and the lowest is $3.00.
Is HRTX stock a good investment in 2026?
According to current analyst ratings, HRTX has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.35. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HRTX stock?
Wall Street analysts predict HRTX stock could reach $4.50 in the next 12 months. This represents a 233.3% increase from the current price of $1.35. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Heron Therapeutics Inc.'s business model?
Heron Therapeutics generates revenue through the development and commercialization of therapeutic treatments aimed at addressing unmet medical needs, primarily in oncology and pain management. The company focuses on creating advanced drug delivery systems that enhance treatment efficacy and safety, which can lead to marketable products that improve patient outcomes.
What is the highest forecasted price for HRTX Heron Therapeutics Inc.?
The highest price target for HRTX is $6.00 from Brandon Folkes at HC Wainwright & Co., which represents a 344.4% increase from the current price of $1.35.
What is the lowest forecasted price for HRTX Heron Therapeutics Inc.?
The lowest price target for HRTX is $3.00 from Serge Belanger at Needham, which represents a 122.2% increase from the current price of $1.35.
What is the overall HRTX consensus from analysts for Heron Therapeutics Inc.?
The overall analyst consensus for HRTX is bullish. Out of 7 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.50.
How accurate are HRTX stock price projections?
Stock price projections, including those for Heron Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 9, 2025 2:57 AM UTC